Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease

Area of Science:

• Biochemistry
• Clinical Pharmacology
• Rare Diseases

Background:

• Increased interest in orphan drug development for rare diseases over the past two decades.
• Significant hurdles remain in clinical trial design for rare disorders.
• Primary mitochondrial disease affects ATP production, impacting cellular energy.

Purpose of the Study:

• To evaluate the safety and tolerability of the novel oral molecule KL1333.
• To explore KL1333's potential to normalize the NAD+:NADH ratio for ATP production.
• To inform the design of later-phase efficacy studies for rare diseases.

Main Methods:

• Phase 1a/1b study in healthy volunteers and subjects with primary mitochondrial disease.
• Incorporated innovative design elements: patient involvement, adaptive design, and exploratory objectives.
• Evaluated safety, tolerability, and novel outcome measures like the 30-s Sit to Stand test and fatigue scales.

Main Results:

• KL1333 demonstrated a safe and well-tolerated profile.
• Dose-dependent gastrointestinal side effects were observed.
• Validated novel outcome measures for primary mitochondrial disease, including fatigue scales and functional tests.
• Data support KL1333 efficacy, showing improvements in fatigue, functional strength, and endurance.

Conclusions:

• Phase 1 studies are valuable for optimizing later-phase efficacy trial design.
• KL1333 shows potential as a therapeutic agent for primary mitochondrial disease.
• Innovative trial designs, including patient input, can overcome rare disease research challenges.